fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-06-01
Acquiring pharma company: Centocor Ortho Biotech (USA)
Acquired biotech company: RespiVert (UK)
Amount: Financial terms were not disclosed.
Terms of the agreement: Centocor Ortho Biotech has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases.
With the acquisition of RespiVert, Centocor Ortho Biotech gains a portfolio of first-in-class, early-stage inhaled treatments for serious lung diseases. RespiVert will continue to maintain its research and discovery presence in London from the Imperial BioIncubator, which is based at the campus of Imperial College London. RespiVert employees will continue to lead ongoing research and drug discovery efforts.
Other: Respivert’s lead compounds, RV-568 and RV-1088, narrow spectrum kinase inhibitors with a unique profile of anti-inflammatory activities, are progressing into clinical development as potential first-in-class treatments for moderate to severe asthma, chronic obstructive pulmonary disease and cystic fibrosis.
The clinical development of RV-568 and RV-1088 will be led by RespiVert in collaboration with scientists at Centocor Research and Development, Inc. The company is not disclosing financial terms.

RespiVert has been financed by Advent Venture Partners, Fidelity Biosciences, Imperial Innovations and SV Life Sciences. Imperial Innovations Group announced that it has realised £9.5m (gross) in cash following the sale of its portfolio company Respivert to Centocor Ortho Biotech Inc. The disposal delivers a 4.7x return on Innovations’ three-year investment.